Immunity to Human Fungal Pathogens: Mechanisms of Host Recognition, Protection, Pathology, and Fungal Interference

Cover image for research topic "Immunity to Human Fungal Pathogens: Mechanisms of Host Recognition, Protection, Pathology, and Fungal Interference"
349.1K
views
212
authors
37
articles
Editors
4
Impact
Loading...
37,841 views
70 citations
Sources of variability in Candida-related infections. The figure illustrates the plethora of variations at the level of the pathogen and the host, which pose serious challenges in the development of an antifungal vaccine. On the pathogen side, Candida species display large phenotypic, morphological, and genetic variation and dynamics; on the host side, candidiasis can occur in different types of patients, with different types of immune system dysfunction or carrying different genetic polymorphisms, and in different anatomical sites. Taken together, this broad and diverse clinical spectrum of the disease makes it difficult to design a “one-size-fits-all” vaccine that would protect all these different patients from all these different types of fungal infection.
Review
27 April 2018
The Elusive Anti-Candida Vaccine: Lessons From the Past and Opportunities for the Future
Gloria Hoi Wan Tso
1 more and 
Norman Pavelka

Candidemia is a bloodstream fungal infection caused by Candida species and is most commonly observed in hospitalized patients. Even with proper antifungal drug treatment, mortality rates remain high at 40–50%. Therefore, prophylactic or preemptive antifungal medications are currently recommended in order to prevent infections in high-risk patients. Moreover, the majority of women experience at least one episode of vulvovaginal candidiasis (VVC) throughout their lifetime and many of them suffer from recurrent VVC (RVVC) with frequent relapses for the rest of their lives. While there currently exists no definitive cure, the only available treatment for RVVC is again represented by antifungal drug therapy. However, due to the limited number of existing antifungal drugs, their associated side effects and the increasing occurrence of drug resistance, other approaches are greatly needed. An obvious prevention measure for candidemia or RVVC relapse would be to immunize at-risk patients with a vaccine effective against Candida infections. In spite of the advanced and proven techniques successfully applied to the development of antibacterial or antiviral vaccines, however, no antifungal vaccine is still available on the market. In this review, we first summarize various efforts to date in the development of anti-Candida vaccines, highlighting advantages and disadvantages of each strategy. We next unfold and discuss general hurdles encountered along these efforts, such as the existence of large genomic variation and phenotypic plasticity across Candida strains and species, and the difficulty in mounting protective immune responses in immunocompromised or immunosuppressed patients. Lastly, we review the concept of “trained immunity” and discuss how induction of this rapid and nonspecific immune response may potentially open new and alternative preventive strategies against opportunistic infections by Candida species and potentially other pathogens.

24,532 views
66 citations
23,054 views
87 citations
In vivo fungal biofilms. (A) Candida albicans biofilm growing on the luminal surface of a rat venous catheter for 24 h. Scanning electron microscopy reveals adherent organisms growing within in an extracellular matrix. (B) Immunohistochemistry of pulmonary tissue from an immunocompromised mouse infected with Aspergillus fumigatus and stained with an anti-galactosaminogalactan antibody. Brown indicates accumulation of galactosaminogalactan-containing biofilm matrix surrounding hyphae growing within pulmonary tissues.
Review
10 January 2018
The Interface between Fungal Biofilms and Innate Immunity
John F. Kernien
2 more and 
Jeniel E. Nett

Fungal biofilms are communities of adherent cells surrounded by an extracellular matrix. These biofilms are commonly found during infection caused by a variety of fungal pathogens. Clinically, biofilm infections can be extremely difficult to eradicate due to their resistance to antifungals and host defenses. Biofilm formation can protect fungal pathogens from many aspects of the innate immune system, including killing by neutrophils and monocytes. Altered immune recognition during this phase of growth is also evident by changes in the cytokine profiles of monocytes and macrophages exposed to biofilm. In this manuscript, we review the host response to fungal biofilms, focusing on how these structures are recognized by the innate immune system. Biofilms formed by Candida, Aspergillus, and Cryptococcus have received the most attention and are highlighted. We describe common themes involved in the resilience of fungal biofilms to host immunity and give examples of biofilm defenses that are pathogen-specific.

14,898 views
117 citations
Schematic representations of the T-cell receptor (TCR) complex and second-generation single-chain variable region (scFv)-chimeric antigen receptor (CAR) and D-CAR. (A) Unmodified endogenous TCR complex and (B) genetically modified TCR complex. The α and β chains are highlighted in different colors. (C) The CD19R-CAR derived from a scFv region of a CD19 antigen-specific mouse monoclonal antibody and (D) the D-CAR+ derived from an extracellular domain of the Dectin-1 receptor. CD19R-CAR and D-CARs shown here have the same signaling domains, derived from costimulatory molecules, such as CD28 and CD3-ζ.
Review
08 January 2018
Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells
Pappanaicken R. Kumaresan
1 more and 
Dimitrios P. Kontoyiannis

Invasive fungal infections (IFIs) cause high rates of morbidity and mortality in immunocompromised patients. Pattern-recognition receptors present on the surfaces of innate immune cells recognize fungal pathogens and activate the first line of defense against fungal infection. The second line of defense is the adaptive immune system which involves mainly CD4+ T cells, while CD8+ T cells also play a role. CD8+ T cell-based vaccines designed to prevent IFIs are currently being investigated in clinical trials, their use could play an especially important role in acquired immune deficiency syndrome patients. So far, none of the vaccines used to treat IFI have been approved by the FDA. Here, we review current and future antifungal immunotherapy strategies involving CD8+ T cells. We highlight recent advances in the use of T cells engineered using a Sleeping Beauty vector to treat IFIs. Recent clinical trials using chimeric antigen receptor (CAR) T-cell therapy to treat patients with leukemia have shown very promising results. We hypothesized that CAR T cells could also be used to control IFI. Therefore, we designed a CAR that targets β-glucan, a sugar molecule found in most of the fungal cell walls, using the extracellular domain of Dectin-1, which binds to β-glucan. Mice treated with D-CAR+ T cells displayed reductions in hyphal growth of Aspergillus compared to the untreated group. Patients suffering from IFIs due to primary immunodeficiency, secondary immunodeficiency (e.g., HIV), or hematopoietic transplant patients may benefit from bioengineered CAR T cell therapy.

29,409 views
62 citations
Fetching...
Recommended Research Topics
Frontiers Logo

Frontiers in Immunology

Host and Pathogen Determinants of Allergic and Invasive Fungal Diseases
Edited by Stéphane Ranque, Joana Vitte, Agostinho Carvalho, Joshua J. Obar
61.1K
views
86
authors
11
articles
Frontiers Logo

Frontiers in Immunology

Immune Interactions with Pathogenic and Commensal Fungi
Edited by Wanqing Liao, Cunwei Cao, Carolina Coelho, Wenjie Fang
65.7K
views
107
authors
17
articles
Frontiers Logo

Frontiers in Immunology

Immune intervention avenues to control fungal infections in immunocompromised individuals
Edited by Som G. Nanjappa, Dimitrios P Kontoyiannis, Sebastian Wurster
21.3K
views
35
authors
5
articles
Frontiers Logo

Frontiers in Immunology

Fungi Infection and Cell Immunity
Edited by Zhengtu Li, Sha Lu, Dominique Ferrandon, Zhongfang Wang, Malcolm D Richardson
27.9K
views
32
authors
6
articles
Frontiers Logo

Frontiers in Immunology

Community Series in Immune Interactions with Pathogenic and Commensal Fungi: Volume II
Edited by Wenjie Fang, Wanqing Liao, Cunwei Cao, Carolina Coelho
29K
views
42
authors
7
articles